

C. P. 3950 Lévis (Québec) G6V 8C6 <u>desjardinslifeinsurance.com/planmember</u> 1-844-410-6485

PRIOR AUTHORIZATION REQUEST

VYVGART (EFGARTIGIMOD ALFA)

PLEASE READ THE INSTRUCTIONS ON THE LAST PAGE OF THIS FORM.

Α	PATIENT IDENTIFICATI	ON – To be completed by the member.							
	Patient's last and first name			Relationship with member			Patient's date of birth		
			🗌 Member	□ Spouse	Dependent child				
	Member's last and first name			Contract No.		Certificate No.			
	No., street, apt. City				I	Province	Postal code		
	Telephone Nos – Home:	Office:	Extensio	on:	Email:				
		equest includes confidential information, please indicate			ned of the decision:				
	By mail (The response to your request will be sent to the address indicated in this section.)								
	Coordination of benefits: If the patient has coverage under a private insurance plan or is enrolled in a provincial drug insurance plan, please submit the request to this plan first. Then send us a copy of the decision notice and this form filled out by the physician, so we can analyze the request.								
		Does the patient have drug coverage under a private insurance plan? ☐ Yes – Please provide a copy of the notice of approval or refusal. → ☐ Copy attached to this form.							
	PRIVATE PLAN	Specify: Name of the insurer:		Contract No.:		_ Certificate No.	:		
		Has a request for reimbursement been submitted und	der your provinc	cial plan?					
	PROVINCIAL PLAN	Yes – Please provide a copy of the notice of approv	val or refusal.	→ □Сору	attached to this for	m.			
		No – Please explain:							
		Is the patient enrolled in a patient support program?	Yes N	0					
	PATIENT SUPPORT PROGRAM	If so – Program name:							
	FROOMAIN	Contact person:		Telephon	e No.:	E	xtension:		
B1	DECLARATION AND AU	ITHORIZATION FOR THE COLLECTION AND CON	ΛΜυΝΙCATIO	N OF PERSON	IAL INFORMATIC	DN .			
	Insurance, strictly for the p the information deemed ne and insurance companies; (when necessary use the per	provided on the claim form is accurate and complete. urposes of managing my file and settling this claim to: (a ecessary to manage my file. The non-exhaustive list of sou b) communicate to the said persons or organizations only rsonal information it may have about me in existing files the ncerning my dependents, insofar as applicable to the claim) collect from ar prces from which the personal inf hat are now close	by person or lega information ma formation about ed. This authoriz	Il entity, or from any y be collected includ me that is deemed r ation is also valid for	y public or parapu les healthcare pro- necessary for the r the collection, u	ublic organization, only ofessionals or facilities, purposes of my file; (c)		
>	Signature of member:				_ Date:				
	Last name and first name of parent/legal guardian (if applicable):								
	Signature of patient or parent/legal guardian (if applicable):				Date:				
B2	CONSENT TO THE COM	IMUNICATION OF PERSONAL INFORMATION TO	O A THIRD PA	RTY					
		aim more efficiently, do you authorize Desjardins Insura f the reasons for the decision on your prior authorization		he patient supp	ort program and th	e attending phy	sician or the attending		
	Yes No								
>	Signature of member:				_ Date:				
	Last name and first name of parent/legal guardian (if applicable):								
	Signature of patient or par	ent/legal guardian (if applicable):			Date:				

CONTINUED ON THE BACK

1

1

ATTENDING PHYSICIAN SECTION – To be completed by the attending physician.												
Physician's last and first name (PLEASE	PRINT)		Licen	ise No.	Specia	alty						
lo., street, suite		City				Province	Postal code					
Telephone No.: Fax No.:												
Signature of physician: Date:												
Drug name		Formulation Strength		Dosage Patie		ight Scheduled	duration of treatm					
Where is the drug administered? Home Physician's office Private clinic Hospital – Inpatient Hospital – Outpatient												
 Make sure to fill out all sections so we can process the request faster. If any information is missing, we will send the form back to the member. In order to consider any diagnosis not mentioned on this form, we need supporting documents (clinical practice guidelines, clinical studies, etc.) that justify the duse in the given context. 												
iagnosis												
Generalized myasthenia gravis												
Other therapeutic indication(s) – Ple	ease specify:											
nformation relating to Generalized myasthenia gravis												
pecify the MGFA class :				rovide the serological test result for anti-acetylcholine receptor antibodies : Positive Negative								
		_	tive 🗆 N	egative								
rovide the serological test result for a	anti-acetylcholine rece	eptor antibodies : 🗌 Posi		egative								
	anti-acetylcholine rece Gravis-Activities of Dai	eptor antibodies : Posi ily Living (MG-ADL) scale :		-								
provide the serological test result for a ndicate the score on the Myasthenia G ndicate the percentage of MG-ADL sco	anti-acetylcholine rece Gravis-Activities of Dai ore attributed to occul	eptor antibodies : Posi ily Living (MG-ADL) scale :		-								
rovide the serological test result for a ndicate the score on the Myasthenia G ndicate the percentage of MG-ADL sco RIOR MEDICATION OR TREATMENT	anti-acetylcholine rece Gravis-Activities of Dai ore attributed to occul T	eptor antibodies : Posicily Living (MG-ADL) scale :	9	-								
rovide the serological test result for a ndicate the score on the Myasthenia G ndicate the percentage of MG-ADL sco RIOR MEDICATION OR TREATMENT las the patient ever used medication o	anti-acetylcholine rece Gravis-Activities of Dai ore attributed to occul T	eptor antibodies : Posicily Living (MG-ADL) scale :	9	%								
rovide the serological test result for a ndicate the score on the Myasthenia G	anti-acetylcholine rece Gravis-Activities of Dai ore attributed to occul T or received treatment	eptor antibodies : Positivity Living (MG-ADL) scale :	9 ? □Yes	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~								
rovide the serological test result for a ndicate the score on the Myasthenia G ndicate the percentage of MG-ADL sco RIOR MEDICATION OR TREATMENT las the patient ever used medication o	anti-acetylcholine rece Gravis-Activities of Dai ore attributed to occul r or received treatment v used or any treatme	eptor antibodies : Positivity Living (MG-ADL) scale :	9 ? □Yes	%		TR	EATMENT PERIOD					
rovide the serological test result for a ndicate the score on the Myasthenia G ndicate the percentage of MG-ADL sco RIOR MEDICATION OR TREATMENT las the patient ever used medication o not, please explain: 5 o, please list any medication already	anti-acetylcholine rece Gravis-Activities of Dai ore attributed to occul r or received treatment v used or any treatme	eptor antibodies : Positivity Living (MG-ADL) scale :	Yes	dition:	aindication	TR From:	YYYY MM DD					
rovide the serological test result for a andicate the score on the Myasthenia G andicate the percentage of MG-ADL scone RIOR MEDICATION OR TREATMENT as the patient ever used medication of not, please explain:	anti-acetylcholine rece Gravis-Activities of Dai ore attributed to occul T or received treatment v used or any treatme NT NAME	eptor antibodies : Positivity Living (MG-ADL) scale :	y Yes s medical control OUTCC	dition:	aindication							
rovide the serological test result for a andicate the score on the Myasthenia G andicate the percentage of MG-ADL score RIOR MEDICATION OR TREATMENT las the patient ever used medication of not, please explain: iso, please list any medication already MEDICATION OR TREATMENT	anti-acetylcholine rece Gravis-Activities of Dai ore attributed to occul T or received treatment v used or any treatme NT NAME	eptor antibodies : Positive (MG-ADL) scale :	y Yes s medical control OUTCC	Mo dition: DME nce Contra	aindication	From:	YYYY MM DD					
rovide the serological test result for a andicate the score on the Myasthenia G andicate the percentage of MG-ADL sco RIOR MEDICATION OR TREATMENT as the patient ever used medication of not, please explain:	anti-acetylcholine rece Gravis-Activities of Dai ore attributed to occul or received treatment v used or any treatme NT NAME	eptor antibodies : Positive in	y Yes s medical control OUTCC Intolerar	Mo dition: DME nce Contra		From: To:	YYYY MM DD YYYY MM DD					
rovide the serological test result for a andicate the score on the Myasthenia G andicate the percentage of MG-ADL sco RIOR MEDICATION OR TREATMENT las the patient ever used medication of not, please explain: for any medication already MEDICATION OR TREATMENT Name: Dose:	anti-acetylcholine rece Gravis-Activities of Dai ore attributed to occul or received treatment v used or any treatme NT NAME	eptor antibodies : Positive in	y Yes s medical control OUTCC Intolerar	No dition: DME Contra nce Contra		From: To: From:	YYYY MM DD YYYY MM DD YYYY MM DD					
rovide the serological test result for a andicate the score on the Myasthenia G andicate the percentage of MG-ADL sco RIOR MEDICATION OR TREATMENT las the patient ever used medication of not, please explain: for any medication already MEDICATION OR TREATMENT Name: Dose: Dose:	anti-acetylcholine rece Gravis-Activities of Dai ore attributed to occul or received treatment v used or any treatme NT NAME	eptor antibodies : Positive provides in the second	<pre>% % % % % % % % % % % % % % % % % % %</pre>	No dition: DME Contra nce Contra	aindication	From: To: From: To:	YYYY MM DD YYYY MM DD YYYY MM DD YYYY MM DD YYYY MM DD YYYY MM DD					
rovide the serological test result for a andicate the score on the Myasthenia G andicate the percentage of MG-ADL sco RIOR MEDICATION OR TREATMENT las the patient ever used medication of not, please explain:	anti-acetylcholine rece Gravis-Activities of Dai ore attributed to occul or received treatment v used or any treatme NT NAME	eptor antibodies : Positive Living (MG-ADL) scale :	<pre>% % % % % % % % % % % % % % % % % % %</pre>	Mo dition: DME Contra nce Contra nce Contra	aindication	From: To: From: To: From:	YYYY MM DD YYYY MM DD YYYY MM DD YYYY MM DD YYYY MM DD					

Indicate the score on the Myasthenia Gravis-Activities of Daily Living (MG-ADL) scale after treament : ______

Please provide objective data that shows a satisfactory clinical or biological response: ____

D INSTRUCTIONS – HOW TO COMPLETE AND RETURN THIS FORM

- 1. Complete sections A and B.
- 2. Ask your physician to complete section C. The member is responsible for assuming any costs incurred to complete this form or to obtain additional information.
- 3. To obtain a reimbursement once the drug has been approved, please use your payment card at the pharmacy or submit your original receipts by mail. Eligible drugs must be dispensed by a pharmacist or a physician, if there is no pharmacist.

4.	Send form:	by fax:	Desjardins Insurance	by mail:	Desjardins Insurance
			Group Insurance, Health Claims, 418-838-2134 or 1-877-838-2134 (toll-free)		Group Insurance, Health Claims C. P. 3950, Lévis (Québec) G6V 8C6

Under its prior authorization program, Desjardins Insurance authorizes the reimbursement of certain drugs that meet criteria that are based, in particular, on clinical practice guidelines and recommendations issued by health technology assessment organizations. The drug will be eligible for reimbursement if it meets the insurer's criteria, if it's not administered in a hospital and if it's not eligible under a government program. If the information on your form is complete, your request will normally be processed within 5 business days.

When the request form is received, it will be assessed in the strictest confidence. In some situations, additional diagnostic or clinical information may be required.

If the treatment continues beyond the authorized period, you will be asked to submit a new request form and provide information that justifies the extension of treatment. If you have a payment card, your pharmacist will be advised that the authorization period is coming to an end. The insurance must be in force and the patient still covered on the date expenses are incurred. This prior authorization is subject to change if, at the time expenses are incurred, the contract has been modified.

When Desjardins Insurance declines a prior authorization request, it is because we need to uphold conditions set out in the contract. It does not mean we are questioning the physician's opinion. If you have any questions, please contact our Customer Contact Centre at the number indicated on page 1 of this form.